William Blair Raises Earnings Estimates for Legend Biotech

Legend Biotech Co. (NASDAQ:LEGN) – Stock analysts at William Blair increased their Q2 2025 earnings per share (EPS) estimates for shares of Legend Biotech in a research note issued to investors on Tuesday, May 13th. William Blair analyst S. Corwin now forecasts that the company will post earnings per share of ($0.22) for the quarter, up from their previous estimate of ($0.33). The consensus estimate for Legend Biotech’s current full-year earnings is ($1.31) per share. William Blair also issued estimates for Legend Biotech’s Q3 2025 earnings at ($0.07) EPS, Q4 2025 earnings at ($0.04) EPS, FY2025 earnings at ($0.88) EPS, Q1 2026 earnings at ($0.03) EPS, Q4 2026 earnings at $0.20 EPS and FY2026 earnings at $0.44 EPS.

Several other analysts have also recently commented on LEGN. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $55.00 target price on shares of Legend Biotech in a research report on Wednesday. Royal Bank of Canada reissued an “outperform” rating and set a $84.00 price objective on shares of Legend Biotech in a research report on Tuesday, April 22nd. Guggenheim reissued a “neutral” rating on shares of Legend Biotech in a research report on Wednesday, March 12th. HC Wainwright reissued a “buy” rating and set a $75.00 price objective on shares of Legend Biotech in a research report on Wednesday, April 16th. Finally, Morgan Stanley reduced their price objective on Legend Biotech from $82.00 to $80.00 and set an “overweight” rating for the company in a research report on Monday, March 17th. One analyst has rated the stock with a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $74.73.

Legend Biotech Stock Performance

LEGN opened at $27.78 on Friday. The firm has a market cap of $5.10 billion, a PE ratio of -29.24 and a beta of 0.20. The business has a fifty day simple moving average of $33.47 and a 200-day simple moving average of $35.85. The company has a quick ratio of 4.90, a current ratio of 4.98 and a debt-to-equity ratio of 0.27. Legend Biotech has a fifty-two week low of $27.34 and a fifty-two week high of $60.87.

Legend Biotech (NASDAQ:LEGN) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.33. The business had revenue of $195.05 million during the quarter, compared to analyst estimates of $190.83 million. Legend Biotech had a negative return on equity of 29.69% and a negative net margin of 66.92%.

Hedge Funds Weigh In On Legend Biotech

Several institutional investors have recently bought and sold shares of LEGN. GAMMA Investing LLC increased its stake in shares of Legend Biotech by 145.4% in the first quarter. GAMMA Investing LLC now owns 1,291 shares of the company’s stock worth $44,000 after purchasing an additional 765 shares during the period. Quarry LP bought a new position in shares of Legend Biotech in the first quarter worth about $48,000. Signaturefd LLC increased its stake in shares of Legend Biotech by 1,052.7% in the fourth quarter. Signaturefd LLC now owns 1,729 shares of the company’s stock worth $56,000 after purchasing an additional 1,579 shares during the period. GF Fund Management CO. LTD. bought a new position in shares of Legend Biotech in the fourth quarter worth about $56,000. Finally, Brooklyn Investment Group increased its stake in shares of Legend Biotech by 1,114.8% in the first quarter. Brooklyn Investment Group now owns 1,725 shares of the company’s stock worth $59,000 after purchasing an additional 1,583 shares during the period. 70.89% of the stock is currently owned by institutional investors.

About Legend Biotech

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).